British drugmaker AstraZeneca said on Monday primary data from a late-stage study to test whether its diabetes drug Farxiga could treat patients hospitalized with COVID-19, who are at risk of developing serious complications, did not meet its main goals.

“The trial did not achieve statistical significance for the primary endpoint of prevention measuring organ dysfunction and all-cause mortality, and the primary endpoint of recovery measuring a change in clinical status (from early recovery to death), at 30 days,” the company said in a statement.

Farxiga was given over 30 days in a global trial of 1,250 patients hospitalized with COVID-19, in addition to the local standard of care. Patients in the trial also had a medical history of hypertension, cardiovascular disease and heart failure, type-2 diabetes, or chronic kidney disease. AstraZeneca said the safety and tolerability profile for Farxiga at 30 days in the trial was consistent with the established safety profile of the medicine.